RT to a vol exposing the thyroid gland

TBI

MIBG therapy (I-131 MIBG therapy)

RT >= 10 Gy to a vol exposing the breasts

OR upper abdominal field radiation that can extend above the diaphragm likely exposing breast tissue at a young age

RT >= 35 Gy to a vol exposing the heart

Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2

RT >= 15 Gy to a vol exposing the heart AND Anthracyclines (doxorubicin isotoxic equivalents)>= 100 mg/m2

Alkylating agents

RT to a vol exposing the testes

Including TBI

RT >=12 Gy to a vol exposing the testicles

Surgery to the spinal cord, sympathetic nerves or pelvis

Hypogonadal

RT to a vol exposing the ovaries

RT >= 30 Gy to a vol exposing the head or the brain

Cisplatin (with or without carboplatin > 1500 mg/m2)

RT to a vol exposing the pancreas

HSCT

RT to a volume exposing the hypothalamus or pituatary gland

Hypothalamic or pituitary tumour

Neurosurgery of the hypothalamus or pituitary gland

RT to a vol exposing the kidneys, heart and associated large vessels

Nephrectomy

Ifosfamide

Platinium based chemotherapy

Nitrosureas

Immunosuppressives treatment and prolonged steroids as anticancer treatment (at least 4 weeks, continuously)

Cranial and/or spinal RT

Methotrexate

Gonadal failure

Growth hormone deficiency

Prolonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatment

HSCT, especially with an history of GVHD

High dose RT

Radiotherapy to a vol exposing the HP region >= 30 Gy

Surgery near or within the HP region

CNS tumours near or within the HP region

Radiotherapy to a vol exposing the HP region< 30 Gy

Hydrocephalus or cerebrospinal fluid shunt(Risk factor for GHD)

Radiotherapy to a vol exposing the HP region

hydrocephalus or cerebrospinal fluid shunt

Radioiodine therapy (I-131 ablation therapy)

Allogenic HSCT

Total thyroidectomy

RT to a vol exposing the head, brain or neck

History of a central nervous system tumor

RT to a vol exposing the brain ANY DOSE

Brain surgery

High dose cytarabine IV (intravenous)

High dose MTX IV

Any Chemotherapy IT (intrathecal)

Vinca-Alkaloids

Cisplatin or carboplatin

RT to a vol exposing the lens

RT to a vol exposing the eye and orbit

RT to a vol exposing the craniofacial area, especially after high doses and at a young age

Surgery to the face, especially at a young age

Surgery of the spine

Surgery of the chest (Does not include CVC pose)

RT to a vol exposing the spine

Spinal or paraspinal malignancies

Cyclophosphamide

RT to a vol exposing the bladder

Cystectomy

Hysterectomy

Pelvic surgery

Spinal cord surgery

RT to a vol exposing the uterus only female

RT to a vol exposing the oral cavity or salivary glands

Chemotherapy

RT to a vol exposing the gastro-intestinal tract

Oesophageal surgery

Abdominal surgery

With a history of chronic GVHD

Anthracyclines (doxorubicin isotoxic equivalents) <100 mg/m2

RT to a vol exposing the lungs

Bleomycin

Busulfan

BCNU Carmustine

CCNU Lomustine

Thoracic surgery

Cisplatin Any dose

Ifosfamide Any dose

Carboplatin Any dose

RT to a volume exposing the liver

Chronic GVHD

Liver surgery

HSCT (irrespective of GVHD)

Mercaptopurine Thioguanine

Dactinomycin

Chronic viral hepatitis

Sinusoidal obstruction syndrome

HSCT (irrespective of GVHD)

Multiple red blood cell transfusions

Splenectomy

RT >= 10 Gy to a vol exposing the spleen

Allogenic HSCT (with or without TBI)

Autologus HSCT conditioned with TBI

Hereditary cancer sd

Any RT including TBI (predominantly in the RT field)

HSCT Especially with a history of skin GvHD

RT to a vol exposing the colon and rectum

RT to a vol exposing the oral cavity

Anthracyclines and/or Mitoxantrone

Epipodophyllotoxins or autologous

Autologous haematopoietic stem cell transplant

Ciclofosfamide, Ifosfamide (particularly if they have a history of severe hemorrhagic cystitis)

RT to a vol exposing the head or brain

RT between 15 and 35 Gy to a vol exposing the heart

Anthracyclines (doxorubicin isotoxic equivalents) between 100 and 250 mg/m2

RT to a vol exposing the kidney or urinary tract